LONDON--(BUSINESS WIRE)--May 16, 2018-- has announced their latest pipeline analysis report on the market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat hyperkalemia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180516005835/en/

Technavio has published a new pipeline analysis report on the hyperkalemia market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.

This report is available at a USD 1,000 discount for a limited time only:

Save more with Technavio. Buy2 reports and get the third for FREE:

Hyperkalemia - market overview

refers to the increased levels of potassium in the blood serum. The word hyperkalemia is derived from three words hyper, Kalium, and emia. Hyper means high, Kalium means potassium, and emia means in the blood. Hyperkalemia is very rare among people who are healthy. The most common cause of hyperkalemia is chronic kidney disease (CKD), type 1 diabetes, and dehydration.

According to a senior analyst at Technavio for , “Severe hyperkalemia can lead to cardiac arrest, which subsequently leads to death. In extreme cases, the patient might be required to go through hemodialysis or hemofiltration, which are two of the most rapid procedures for the extraction of potassium from the body.”

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Hyperkalemia segmentation

This market research report segments the market based on therapies employed that includes monotherapy, indication coverage (hyperkalemia and severe hyperkalemia), RoA (oral), types of molecules used (small molecule), therapeutic modalities (small molecules, and phytotherapy), targets for drugs under development (SRC kinase and unknown), drugs under development (phase III and pre-clinical), and recruitment status (recruiting, active not recruiting, and completed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005835/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH INFECTIOUS DISEASES PHARMACEUTICAL RESEARCH OTHER SCIENCE DIABETES SCIENCE GENERAL HEALTH

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 05/16/2018 09:33 AM/DISC: 05/16/2018 09:33 AM

http://www.businesswire.com/news/home/20180516005835/en